文献速递衰弱、肌少症与跌倒老年慢病共病管理

靶向衰老机制药物延缓年龄相关疾病并促进健康寿命:NIA研讨会纪要

Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2023-01-01

美国国家老龄化研究所(NIA)研讨会综述了靶向衰老机制以延缓年龄相关疾病、延长健康寿命的药理干预研究。专家评估了senolytics、NAD+增强剂和二甲双胍的临床前与临床证据,指出这些药物具有改善健康寿命的潜力,但人体研究有限且结果不一,尚需更多研究验证获益、安全性、目标人群和长期结局。

要点

  • Senolytics在啮齿类临床前研究中改善健康寿命,人体研究正在进行中。
  • 补充NAD+前体在模型生物中似可延长健康寿命,但人体研究有限且结果不一。
  • 二甲双胍临床前研究提示改善寿命和健康寿命,观察性研究提示预防年龄相关疾病获益。

核心结论

  • 临床前和新兴临床研究提示,所综述的药物具有改善健康寿命的潜力,但尚需大量进一步研究证明获益、广泛使用的总体安全性、合适的目标人群及长期结局。

研究设计与样本

  • 美国国家老龄化研究所(NIA)研讨会,由科学内容专家对senolytics、NAD+增强剂和二甲双胍的研究进行文献综述和领域现状评估。

主要发现

  • 细胞衰老随年龄增加,临床前研究证明使用senolytic药物改善啮齿类动物的健康寿命,使用senolytics的人体研究正在进行中。
  • 通过补充烟酰胺核糖和烟酰胺单核苷酸等前体增加NAD+在模型生物中似乎延长健康寿命,但人体研究有限且结果不一。
  • 二甲双胍临床前研究提示改善寿命和健康寿命,观察性研究提示对预防几种年龄相关疾病有获益,临床试验正在进行以考察其对健康寿命和衰弱预防的作用。

局限性

  • 人体研究有限且结果不一(针对NAD+增强剂)。
  • 尚需大量进一步研究证明获益、广泛使用的总体安全性、合适的目标人群及长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The geroscience hypothesis posits that by targeting key hallmarks of aging we may simultaneously prevent or delay several age-related diseases and thereby increase healthspan, or life span spent free of significant disease and disability. Studies are underway to examine several possible pharmacological interventions for this purpose. As part of a National Institute on Aging workshop on the development of function-promoting therapies, scientific content experts provided literature reviews and state-of-the-field assessments for the studies of senolytics, nicotinamide adenine dinucleotide (NAD+) boosters, and metformin. Cellular senescence increases with age, and preclinical studies demonstrate that the use of senolytic drugs improves healthspan in rodents. Human studies using senolytics are in progress. NAD+ and its phosphorylated form, NADP+, play vital roles in metabolism and cellular signaling. Increasing NAD+ by supplementation with precursors including nicotinamide riboside and nicotinamide mononucleotide appears to extend healthspan in model organisms, but human studies are limited and results are mixed. Metformin is a biguanide widely used for glucose lowering, which is believed to have pleiotropic effects targeting several hallmarks of aging. Preclinical studies suggest it improves life span and healthspan, and observational studies suggest benefits for the prevention of several age-related diseases. Clinical trials are underway to examine metformin for healthspan and frailty prevention. Preclinical and emerging clinical studies suggest there is potential to improve healthspan through the use of pharmacologic agents reviewed. However, much further research is needed to demonstrate benefits and general safety for wider use, the appropriate target populations, and longer-term outcomes.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Espinoza SE, Khosla S, Baur JA, et al. Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop. J Gerontol A Biol Sci Med Sci. 2023. PMID: 37325957. doi:10.1093/gerona/glad034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。